drug · antibody
blinatumomab
Marketedupdated 3mo agoby $AMGN AMGEN INC🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 12 investigational indications.
targets
B-lymphocyte antigen CD19T cell surface glycoprotein CD3
all catalysts(25)
approval · 23
Dec 3, 2014
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Aug 30, 2016
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Aug 30, 2016
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
May 3, 2017
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Jul 11, 2017
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Nov 30, 2017
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Mar 29, 2018
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Apr 10, 2018
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Apr 18, 2019
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Apr 18, 2019
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Mar 20, 2020
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Mar 11, 2021
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Mar 11, 2021
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Mar 11, 2021
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Feb 18, 2022
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Dec 5, 2022
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Jun 20, 2023
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Jun 20, 2023
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Feb 8, 2024
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Jun 14, 2024
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Dec 17, 2024
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Apr 29, 2025
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
Oct 21, 2025
approval
$AMGN415.21-0.63%
BLINCYTO (BLINATUMOMAB) — FDA approval
blinatumomab
→
phase 1 2 completion · 1
Trials studying blinatumomab
- phase2A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
- phase2A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- phase3A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
- phase2Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
- phase2Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- phase1Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
- phase1Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
- phase3A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 27m ago
Found something off?
comments(0)
5-min edit window · permanent after that